[PBBANK] QoQ Cumulative Quarter Result on 31-Mar-2016 [#1]

Announcement Date
20-Apr-2016
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2016
Quarter
31-Mar-2016 [#1]
Profit Trend
QoQ- -75.71%
YoY- 4.97%
View:
Show?
Cumulative Result
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Revenue 20,102,740 15,018,657 9,987,557 5,007,301 19,181,550 14,252,504 9,337,981 66.33%
PBT 6,554,032 4,761,321 3,203,079 1,651,558 6,491,395 4,633,619 3,019,825 67.23%
Tax -1,286,597 -993,155 -687,427 -406,498 -1,370,156 -1,019,551 -622,722 61.86%
NP 5,267,435 3,768,166 2,515,652 1,245,060 5,121,239 3,614,068 2,397,103 68.61%
-
NP to SH 5,206,875 3,724,093 2,485,943 1,229,790 5,062,152 3,569,724 2,368,329 68.67%
-
Tax Rate 19.63% 20.86% 21.46% 24.61% 21.11% 22.00% 20.62% -
Total Cost 14,835,305 11,250,491 7,471,905 3,762,241 14,060,311 10,638,436 6,940,878 65.54%
-
Net Worth 34,213,222 32,826,175 32,443,500 31,111,671 31,230,991 29,640,055 29,322,255 10.78%
Dividend
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Div 2,239,666 1,003,988 1,003,988 - 2,162,436 926,758 926,758 79.60%
Div Payout % 43.01% 26.96% 40.39% - 42.72% 25.96% 39.13% -
Equity
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Net Worth 34,213,222 32,826,175 32,443,500 31,111,671 31,230,991 29,640,055 29,322,255 10.78%
NOSH 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 0.00%
Ratio Analysis
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
NP Margin 26.20% 25.09% 25.19% 24.86% 26.70% 25.36% 25.67% -
ROE 15.22% 11.34% 7.66% 3.95% 16.21% 12.04% 8.08% -
Per Share
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
RPS 520.59 388.93 258.64 129.67 496.74 369.09 241.82 66.33%
EPS 134.84 96.44 64.38 31.85 131.09 92.44 61.33 68.67%
DPS 58.00 26.00 26.00 0.00 56.00 24.00 24.00 79.60%
NAPS 8.8601 8.5009 8.4018 8.0569 8.0878 7.6758 7.5935 10.78%
Adjusted Per Share Value based on latest NOSH - 3,882,138
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
RPS 103.57 77.37 51.45 25.80 98.82 73.43 48.11 66.33%
EPS 26.82 19.19 12.81 6.34 26.08 18.39 12.20 68.66%
DPS 11.54 5.17 5.17 0.00 11.14 4.77 4.77 79.73%
NAPS 1.7626 1.6911 1.6714 1.6028 1.609 1.527 1.5106 10.78%
Price Multiplier on Financial Quarter End Date
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Date 30/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 -
Price 19.72 19.82 19.40 18.78 18.52 17.52 18.72 -
P/RPS 3.79 5.10 7.50 14.48 3.73 4.75 7.74 -37.74%
P/EPS 14.62 20.55 30.13 58.97 14.13 18.95 30.52 -38.64%
EY 6.84 4.87 3.32 1.70 7.08 5.28 3.28 62.86%
DY 2.94 1.31 1.34 0.00 3.02 1.37 1.28 73.64%
P/NAPS 2.23 2.33 2.31 2.33 2.29 2.28 2.47 -6.55%
Price Multiplier on Announcement Date
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Date 02/02/17 20/10/16 28/07/16 20/04/16 03/02/16 22/10/15 30/07/15 -
Price 20.14 19.80 19.56 19.02 18.38 18.64 18.88 -
P/RPS 3.87 5.09 7.56 14.67 3.70 5.05 7.81 -37.24%
P/EPS 14.94 20.53 30.38 59.72 14.02 20.16 30.78 -38.10%
EY 6.70 4.87 3.29 1.67 7.13 4.96 3.25 61.62%
DY 2.88 1.31 1.33 0.00 3.05 1.29 1.27 72.17%
P/NAPS 2.27 2.33 2.33 2.36 2.27 2.43 2.49 -5.95%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment